Transcription factors (TFs) reprogram cell states by exerting control over gene regulatory networks and the epigenetic landscape of a cell. Artificial transcription factors (ATFs) are designer regulatory proteins comprised of modular units that can be customized to overcome challenges faced by natural TFs in establishing and maintaining desired cell states. Decades of research on DNA-binding proteins and synthetic molecules has provided a molecular toolkit for ATF design and the construction of genome-scale libraries of ATFs capable of phenotypic manipulation and reprogramming of cell states. Here, we compare the unique strengths and limitations of different ATF platforms, highlight the advantages of cooperative assembly, and present the potential of ATF libraries in revealing gene regulatory networks that govern cell fate choices.
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Keywords: artificial transcription factor; cell fate; reprogramming Natural, artificial, and synthetic transcription factors in cellular reprogramming Transcription factors (TFs) control the expression of genes and dynamically regulate gene regulatory networks to induce changes in cellular state. They are the primary effectors of interpreting a genotype to yield a full complement of cellular phenotypes in an organism. External as well as internal cellular signals instruct TFs to regulate distinct sets of gene expression and sculpt the epigenetic landscape in response to those cues [1, 2] . During development and tissue regeneration, TFs drive cell fate specification to functionally distinct cell types and serve to maintain the identity of the cell once it is established [3, 4] .
Recently, TFs have been used in a variety of contexts to obtain a number of desired cell states [5] [6] [7] [8] [9] [10] [11] . Perhaps this should not come as a surprise, given the integral role of TFs in regulating cell fates during development. In an early demonstration of their primacy, the ectopic expression of MyoD induced fibroblasts to transdifferentiate to stable myoblasts [12] . Since then, manipulation of TF expression has revealed the potential for even more dramatic traversals in cell fate. A striking example is the reprogramming of mouse fibroblasts to a pluripotent state by Oct4, Sox2, Klf4, and c-Myc [13] . These TFs, along with other sets, have also been shown to reprogram human somatic cells to a pluripotent state [14] [15] [16] . The ease with which one can reprogram somatic cells to a pluripotent state is a major advance that has fueled rapid progress across a wide array of scientific and technological disciplines. Reprogramming of cells derived from individuals afflicted with genetic disease has propelled the development of personalized medicine and has further highlighted the need to generate specific cell types for disease modeling, drug screening, and tissue engineering [17] [18] [19] [20] [21] .
While cocktails of select TFs have been successful in generating some cell types of interest, the process of identifying natural TFs that can induce specific cell fate changes has presented several substantive challenges. First, the process of selecting relevant TFs from the approximately 1500 that have been identified in the human genome must be informed by prior knowledge of their expression profiles and function during differentiation to a desired cell type [22] . Identification of TFs expressed in the desired cell type may only reflect those TFs that are necessary to maintain cell fate, not those that may be temporally expressed and regulated to establish it [23] . Second, expressing the correct combinations and levels of TFs required to drive cell fate transitions involves a trialand-error method of screening that is often prone to failure and requires substantial time, labor, and financial resources. Third, natural TFs are subject to feedback regulation, dependence on partner proteins that may not be expressed in the starting cell type, epigenetic barriers that prevent binding to target sites in the genome, and other processes that prevent departure from a given homeostatic state. The majority of such challenges can be circumvented by artificial transcription factors (ATFs) that directly target key gene regulatory networks that govern cell fate changes (Fig. 1A) [24-27]. Importantly, libraries of ATFs can also be used to screen thousands of genes in parallel to produce a phenotype of interest without prior knowledge of relevant natural TFs or gene regulatory networks [28] [29] [30] [31] [32] [33] [34] [35] .
Artificial transcription factors are composed of modular domains that can be customized to suit a variety of applications (Fig. 1B) . The DNA Binding Domain (DBD) confers sequence specificity and can be tailored to target cognate sites in the genome with varying degrees of affinity and specificity [36] [37] [38] . A variety of DBDs have been utilized, including zinc fingers (ZFs), transcription activator-like effectors (TALEs), and the microbial RNA-guided clustered regularly interspaced short palindromic repeat -Cas (CRISPR-Cas) system, each of which have positive attributes as well as critical limitations that must be carefully balanced depending on their intended purpose ( Fig. 2A) . The DBD delivers an Effector Domain (ED) to specific genomic loci (Fig. 2B) . The ED can be used to activate or repress transcription of targeted genes by recruiting or blocking transcriptional machinery [36, [38] [39] [40] [41] . Additionally, the ED can be designed to enzymatically remodel chromatin, place epigenetic marks to change the binding site's accessibility to natural TFs, or induce chromatin looping [42] [43] [44] [45] [46] [47] [48] [49] [50] . A nuclease ED can also be used to generate sequence-specific nucleases in tandem with nonhomologous end joining (NHEJ) or homology directed recombination (HDR) for genome-editing [51, 52] . While less frequently used, an Interaction Domain (ID) can also be incorporated to enable cooperative binding with natural TFs or other ATFs, enzymes, or partner proteins [53] [54] [55] [56] . The inclusion of an ID in ATF design allows for an added layer of complexity and regulatory control through the ability to cooperatively associate with endogenous TFs or other ATFs at a broader set of genomic loci. In addition to the standard protein-based modules, synthetic DNA-targeting molecules, such as polyamides [57] and oligonucleotides [58] [59] [60] , or RNA-based or synthetic activation modules [61] [62] [63] [64] [65] , may also be employed to serve as synthetic TFs (Syn-TFs), especially when transient gene regulation is desired without delivery of genetic material. For transient gene regulation, transcription factors can also be delivered as mRNA or recombinant proteins with cell-penetrating peptides for transient gene regulation [66, 67] . In generating a specific ATF, each of these design features must be carefully considered depending on their intended downstream application.
ATF platforms

CRISPR-Cas
Given its ease-of-use, the CRISPR-Cas system has rapidly become the most widely used DNA targeting approach [68, 69] . The CRISPR-Cas system typically utilizes a stretch of 17-20 nucleotides in a single-guide RNA (sgRNA) to target specific sequences in the genome [70] [71] [72] . Its innate nuclease activity makes this platform an ideal choice for genome-editing, and several bioinformatic tools exist for designing sgRNA sequences that display high sequence specificity and minimal off-target effects [73, 74] . The nuclease activity can be disabled and an ED can be incorporated to enable function as an ATF [75] . Multiple sgRNAs can be readily designed and synthesized, making the CRISPR-Cas system amenable for testing more than one target simultaneously. A key limitation in design is that a protospacer adjacent motif (PAM) must exist in the target sequence. Additionally, the CRISPR-Cas protein is large in size at close to 1400 amino acids and requires a sgRNA for specificity, resulting in a complex over 150 kDa that cannot be as readily delivered to cells as smaller molecules of equal functionality. For genome-scale cellular screens, efficiency in delivery should be considered, especially when the positive outcome is considered a rare event. While the CRISPR-Cas system is capable of upregulating silenced genes, increasing the expression of genes that are already expressed at low or moderate levels remains a challenge [29] . Compared to other DBDs, the magnitude of change in transcription by CRISPRCas systems is not as robust [76] . Modifications can be made to increase transcriptional activation, but they require additional effector domains that further increase the size or number of components [77] [78] [79] . Library screens using pooled and arrayed sgRNAs have been utilized in activation, repression, and knockout library screens [72, 80, 81] . While the CRISPR-Cas systems can be used for gene activation or repression, the requirement of a specific sgRNA for every targeted genomic locus imposes logistical challenges on the use of CRISPR-Cas to simultaneously target multiple regulatory elements at different genes in a cell. Current sgRNA libraries designed to specifically target single loci limit the use of this platform in gain-of-function screens where sets of genes are required to reprogram cell fates [75] .
TALEs
TALEs are comprised of 34 amino acid tandem repeats that form a superhelical structure that wraps around the major groove of DNA [82, 83] . A single repeat consists of two a-helices, and residues 12 and 13 between the two helices confer nucleobase specificity. Typically, 10-15 repeats allow for the precise targeting of desired genomic loci [84] . An advantage of using TALEs as a DBD is the fidelity of each repeat to the recognition code, enabling the design of highly specific targeting modules [85] . The first repeat at the N-terminus specifies a thymine, so target sequences should be selected with this design restriction in mind. While their repetitive nature makes them difficult to synthesize, strategies to overcome cloning hurdles have been addressed [86, 87] . TALEs minimally require an 11-mer target sequence for sufficient upregulation of a gene, and an 11-mer TALE library capable of upregulating transcription at binding sites has been designed and validated [88] as well as a TALE nuclease library for knockout screens [84, 89] . While their specificity is an advantage for designing ATFs with minimal offtarget effects, design of TALE-ATFs that can target multiple closely related binding sites across the genome is more challenging. Thus, the tolerance of natural TFs for binding sites that deviate from the consensus binding site motif is a parameter that is not readily accommodated by TALE or CRISPR-based ATFs.
Synthetic molecules
The use of synthetic small molecules capable of binding DNA is an attractive nonprotein alternative to regulating transcription. While protein-based ATFs can be delivered to cells transiently or long-term through integration into the genome, treatment with small molecules allows for more finely tuned control of dosage and timing of transcriptional regulation without the introduction of genetic material. In the context of cell differentiation and reprogramming to pluripotency, the use of small molecules instead of proteinbased TF methods has been an area of active research due to the ability to generate cells without the need to deliver genetic material that may permanently alter the genome of the cell [90] [91] [92] [93] . While many of the smallmolecules that have been effective in cell fate changes are drugs that modulate signaling pathways, small molecules that bind specific DNA sequences and regulate transcription can also be rationally designed.
Polyamides composed of N-methylpyrrole and Nmethylimidazole repeats have been shown to be a promising DBD for the construction of synthetic TFs (Syn-TFs) [36, 53, 94] . Polyamides are capable of binding in the minor groove of DNA with high affinity and rely on a set of pairing rules that determine their sequence specificity [57, 95] . Synthetic activation and repression domains have been developed that can be conjugated to the polyamide DBD, allowing for transcriptional regulation at their binding sites [53, 63, 96] . Over the past few years, both polyamides conjugated to histone deacetylase inhibitors and polyamides capable of blocking TF-DNA binding interactions have been used to activate pluripotency networks and drive differentiation to mesoderm states respectively [97] [98] [99] . More recently, polyamide-based synthetic elongation factors have been developed to target single genes that cause inherited diseases [53] . Challenges regarding cellular uptake of these molecules can potentially be overcome through the conjugation of isophthalic acid, incorporation of aryl turns, or other modifications capable of enhancing uptake [100, 101] . The ability of polyamides to bind specific sequences with high affinity and regulate transcription without leaving a genetic footprint make them promising candidates for controlling cell fates once key regulators driving cellular differentiation have been identified. However, genomescale libraries for screening have yet to be developed for the de-novo identification of relevant regulators of cell fate, and while methods for mapping the genomic binding of small molecules have been developed, library screens remain challenging [102] .
Zinc fingers
Most ZFs are comprised of a Cys 2 His 2 motif that is present in an array of natural DNA-binding proteins in eukaryotes and is the most abundant DBD amongst all TFs encoded in the human genome [103] . Each 30-amino acid ZF contains two antiparallel b-strands and an a-helix that binds the major groove of DNA [104] . Four key amino acid residues make nucleobase contacts that establish the specificity of each ZF for sequences of three base pairs [105] [106] [107] . They are capable of binding methylated DNA and heterochromatin, allowing them to access genomic features regardless of cell state [108] . ZFs can be linked in tandem to target larger base pair sequences. However, adjacent ZFs can alter the sequence recognition by neighboring fingers, confounding efforts to rationally design ZF-ATFs that target large sequences [38] . When there are more than three ZFs within an ATF, subsets of ZFs are capable of binding undesired sites with sufficient affinity to elicit off-target effects [109] . Therefore, targeting of specific sequences must be verified through additional assays. A major advantage is that of size, because ZFs are much smaller in size than other DNA-binding proteins, their packaging and delivery to cells is efficient even when many ZFs are linked in tandem. This is particularly advantageous when attempting to combinatorially target many genomic loci by introducing multiple ATFs to a cell that target different consensus sequences. ZF-ATF libraries have been designed and implemented in a variety of contexts [28, 35, [110] [111] [112] [113] . Due to difficulties in designing ZF-ATFs that target larger sequences and their susceptibility to off-target binding, ZF-ATF platforms may require added optimization to target unique genomic loci and regulate single genes. However, ZF-ATF libraries are particularly well-suited for identifying factors that target multiple regulatory elements with closely related binding sites. Often, multigene networks drive complex phenotypes that are a product of coordinated changes in the expression of multiple genes. Often binding sites are not strictly conserved, retaining core sequences but using sites of different affinities to drive nuanced and timed expression of a web of genes to effect changes in cell fate. Not only do ZF-ATFs accommodate such variations on the core binding site, but the ease of delivering a set of distinct ATFs that are each capable of targeting numerous genomic loci allows for more broad perturbations in the cellular state that are difficult to achieve with other ATF platforms.
Design and application of ATFs in reprogramming cell fates
Natural TFs typically bind short sequences (4-10 bp) and have hundreds to thousands of binding sites across the genome. As noted earlier, while TALEs and CRISPR-Cas proteins can be designed to bind highly unique sites in the genome, it may be necessary for the designed factor to bind multiple sites to alter the expression of many downstream genes simultaneously. To induce the global changes to the transcriptome required for cell fate changes, it may be advantageous for the designed factor to more closely mimic natural TFs. Therefore, ZF-ATFs that bind many sites in the genome while maintaining a binding affinity that rivals natural TFs are promising candidates for inducing cell fate changes. Recently, we created and applied a ZF-based ATF library to replace factors used in the reprogramming of mouse fibroblasts to an induced pluripotent state [28] . Inducing pluripotency requires drastic changes to the transcriptome and epigenome.
We asked whether Oct4, a key regulator in the pluripotency network and one of the four Yamanaka factors, could be replaced by ATFs [114] . To test this, a library of high complexity capable of targeting multiple gene regulatory networks was designed.
The ATF library was built using an EGR1 scaffold containing three Cys 2 His 2 ZF-ATFs linked in tandem to target 9 base pair sequences or 18 base pairs with dimerization. The codons for key DNA-binding residues were replaced with 5 0 -VNN-3 0 codons (where V is A, C, or G) to randomly incorporate 16 possible amino acids while preventing the incorporation of all three canonical stop codons beginning with a U/T (Fig. 3A) . With 12 key residues per ZF-ATF, this results in 12 16 or 2.8 9 10 14 possible combinations. While it is neither possible nor desirable to attain this degree of complexity, optimizing every step of the process results in a library with over 2.6 million ATFs with different combinations of DNA recognition sequences. This level of protein complexity still exceeds by fivefold all possible sequence permutations of a 9-base pair site in the genome. Each of these ATFs bears a potent activation domain to recruit the general transcriptional machinery and upregulate transcription of genes that are proximal to the binding sites. While previous studies have optimized ZF-ATF libraries to induce phenotypic changes in cells [31,33,115], a distinguishing feature of our library is the inclusion of an interaction domain (ID).
Combinatorial assembly expands the range of ATF function and potency
Incorporation of an ID allows for ATF dimerization upon binding to 18 base pair sequences as homo-and heterodimers [55] . An ID can be a small molecule, a short peptide, a domain, or even a full protein. A peptide selected by phage display that binds the surface of the first zinc finger enables dimerization between two ATFs as homodimers or heterodimers only on the target DNA site. The affinity of the interactions is carefully balanced to ensure that the complex is only stabilized upon binding to a DNA cognate site. An exciting feature of this design is that an ID could potentially enable an ATF to bind endogenous factors that are only expressed during particular cell states that would confer the ability to function in a biologically regulated manner. As per the design, inclusion of the ID with the three zinc fingers of EGR1 elicits maximal upregulation of the greatest number of genes compared to ZFs that lack the ability to dimerize. The dimerization of the ATFs likely allows them to target an additional subset of genes that are inaccessible to individual ATFs, allowing for greater perturbations in the transcriptome. This is consistent with previous findings on the binding specificity of cooperatively assembling DNA-binding molecules [116] . Based on affinity measurements of the cooperative binding of two ZF pairs, it would be reasonable to expect that an ATF bearing two ZFs and an ID would suffice to target 12-bp binding sites [55] . However, this design only triggered a twofold change in transcription, while an ATF bearing three ZFs and an ID elicited a 300-fold change [28] . This striking difference provides some hints at the threshold of binding affinities that must be attained to achieve optimal sequence specificity and residence time at targeted genomic loci to effect biologically meaningful gene regulation. Thus, a library of ATFs bearing three zinc fingers and an ID was developed to reveal sets of ATFs capable of replacing the natural TFs in the induction of pluripotency in mouse embryonic fibroblasts [28] .
ZF-ATF library design and experimental system
The ATF library was designed in a manner that allowed for the selection of successful integration events. It was delivered to cells using a lentiviral system in doses capable of integrating multiple ATFs into each cell, generating a heterogenous population of cells expressing different combinations of ATFs (Fig. 3B) . In the first application, the ATF library screen revealed 11 unique combinations of 2 to 10 ATFs sufficient for replacing Oct4 in the induction of pluripotency. Remarkably, different combinations of ATFs that appeared to have different binding site preferences were identified, suggesting different routes to stimulating the pluripotency gene network. It is important to note that continued expression of the ATFs was not necessary to maintain pluripotency, indicating that the ATFs induced cells to embark on paths to a stable pluripotent state. RNA-sequencing and in vitro binding assays combined with bioinformatic analysis revealed that the expression of Oct4 was not a result of direct targeting by the ATFs, but was instead activated indirectly as a downstream target of other gene networks. A differential expression analysis comparing iPS lines generated with ATFs and iPS lines generated with the Yamanaka factors revealed different expression profiles at the early stages of reprogramming, suggesting the activation of different gene regulatory networks capable of inducing pluripotency. These results were particularly interesting, not only because we were able to replace a key TF in the induction of pluripotency, but because this experiment served as a proof-of-concept for using the ATF library as an unbiased tool for the discovery of unanticipated regulatory paths. While other groups have demonstrated that it is possible to design ATFs that specifically activate known pluripotency genes or neural genes, this forward genetics approach enables conversions to elusive cell types without a priori knowledge of cell fate-defining regulatory networks when the key regulators driving cell fate decisions are unknown [26] [27] [28] 117] .
Plasticity factors
Interestingly, a few ATFs are recurrently isolated in other cell fate conversions in our library screens (A. Eguchi, E. A. Heiderscheit, M. C. Spurgat, M. J. Wleklinski, D. Bhimsaria, T. J. Kamp & A. Z. Ansari, unpublished). In sequencing the original ZF-ATF library these factors are not over-represented, therefore their reappearance in different cell fate conversion screens from a library with a complexity of over 2.6 million suggests that they may increase cellular plasticity. Previously described approaches to reprogramming cell fates have utilized the transient expression of a subset of the Yamanaka factors and a small molecule cocktail to achieve an activated cell state with enhanced plasticity [118, 119] . While the cell activation and signaling-directed (CASD) approach still depends on the external delivery of Oct4, Sox2, and Klf4, it permits the circumvention of a fully induced pluripotent state to enable signal-responsive conversion into other desired cell states. It is conceivable that "plasticity inducing" ATFs may be targeting effectors akin to the CASD approach to universally induce an activated cellular state to reprogram cells, highlighting another interesting outcome of utilizing a high-throughput library for the functional screening of ATFs.
These studies exemplify how ATFs can serve as powerful alternatives to natural TFs in driving and identifying underlying gene regulatory networks that govern cell fate choices. However, we reiterate the importance of carefully considering the ATF platform and design elements with regard to their intended downstream purpose. Platforms useful for regulating specific genes may not be capable of targeting a sufficient number of sites to generate the broad perturbations in cellular state necessary for inducing more complex changes in phenotype (Fig. 4) . Likewise, platforms with low binding specificity or small effects on transcriptional regulation may not be suitable for the targeting of specific genes in gain-or loss-of-function studies. Epigenetic barriers of the starting cell type remain an inherent challenge in the use of transcription factors, particularly in settings where inaccessible regions of the genome must be activated for the desired cell fate change. Efforts to alter chromatin accessibility at key genomic loci through the use of effector domains or small molecules that trigger remodeling of the chromatin environment would lower such epigenetic barriers and enable the regulation of targeted gene networks. Fig. 4 . ATFs can target genes and gene regulatory networks. Natural TFs bind short sequences at potentially hundreds of sites in the genome to regulate the expression of genes. ZF-ATFs can be constructed to closely mimic these natural TFs and allow for the targeting of multiple regulatory elements. While CRISPR and TALE-based ATF platforms have high specificity for targeting unique sites within the genome, they may not be capable of generating the perturbations necessary to achieve cell state transitions.
Future prospects for ATFs in cellular reprogramming
The ability to target the genome and perform library screens make ATFs promising candidates for future studies that intend to interrogate cell state dynamics. Many cell types have eluded the standard natural TF and small molecule approaches, and it may be necessary to explore the use of ATFs to directly identify and modulate key gene regulatory networks capable of achieving these rare or ephemeral cell states. Instead of relying on natural TFs and the manipulation of extra-and intracellular signaling pathways with small molecules, direct targeting of potential relevant downstream effectors capable of driving these cell fate changes is now possible with complex ATF libraries.
The ability to directly target and manipulate the genome also offers the opportunity to explore the dynamics of cell state transitions. The potential to stabilize transient states as cells are reprogrammed or proceed through different lineages could offer insights into the basic mechanisms driving cell fate changes and the regulatory mechanisms responsible for maintaining and perturbing cell homeostasis [120, 121] . ATFs may also be capable of stabilizing hybrid states where cells are receiving cues to proceed through orthogonal lineages. By stabilizing these hybrid states, further experiments could be more easily performed at the population level to interrogate the mechanisms through which cell progenitors diverge into segregated lineages and the contributions of stochastic and deterministic processes in establishing cell fate [122, 123] . Conversely, ATFs could also be employed at these hybrid states to more stably direct progenitors to one of their potential cell fates, mitigating stochastic effects and increasing the efficiency of differentiation to the desired cell type. It is also conceivable that generating populations stabilized in transient or hybrid states could enable more robust screening and study of pharmacological agents that could potentially function at these stages and overcome challenges posed by studying uncommon cell states within heterogenous populations [124, 125] .
Conclusion
The use of TFs to regulate gene networks and produce changes in cell state have had mounting success over the years. However, identifying a minimal set of natural TFs that drive cell fate changes remains laborintensive and challenging. Emerging technologies in ATF design have built upon decades of research in natural DNA-binding proteins, allowing them to be custom-tailored for a variety of purposes. Libraries of ATFs have been increasingly used in loss-and gainof-function screens, and have recently been used to produce more drastic changes, such as cell fate conversions. Their ability to be used in the de-novo discovery of genes and classification of gene networks relevant to different processes holds promise as a tool for basic research. Nonprotein based methods utilizing small molecules that can be rationally designed to act as ATFs have also begun to emerge as potential regulators of gene expression and cell fate, allowing for transcriptional regulation without the introduction of genetic material. However, along with these emerging technologies comes the need for careful consideration of ATF design, which we have highlighted.
Acknowledgments
We are grateful to members of the Ansari lab for helpful discussions and Laura Vanderploeg for help with figure graphics. 
